25 news items
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
Lung cancer is the leading cause of cancer deaths globally. Non-small cell lung cancer (NSCLC) is one of the most
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
of death by 22%, demonstrating a median OS of 21.7 months versus 18.9 months with cisplatin-gemcitabine alone (Hazard Ratio [HR] 0.78; 95% Confidence
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
BMY
12 Apr 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
BMY
JNJ
MRK
10 Apr 24
and this time round, they are turning to the world’s most common causes of death- cancer and heart disease.
Johnson & Johnson
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
BMY
8 Apr 24
CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted
ye0eusfg3 0k3tgxqk8pga0f
BMY
8 Apr 24
for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death
In the pooled safety
7uomfbzw9vitq4nqttihxh5iwqb9 3ir0e81bvx190rl
BMY
TSVT
5 Apr 24
in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
mxji1pp7qp1fx jxtvhrnhcefoczur43cxinvmz9526b2vk1tc2f970g13
BMY
TSVT
5 Apr 24
in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
9g5 imuw93o7iwcxsoasyedss069v
BMY
4 Apr 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
2b367mznfl4xosu44dbdbbnex7ph8053ddqc
BMY
2 Apr 24
).
Safety results were consistent with previous MDS studies, and progression to acute myeloid leukemia and total deaths were
9v546oxdvpshrnq6okgn6f5 gl0
BMY
31 Mar 24
, regarding Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
nuua48jw2j4m utpmaf33swx8l
BMY
27 Mar 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
pedwk1ebtrxjnaz9mv2z5bosxwa0ck2dve1qhs7008sj8gfd4zrzuq9
BMY
MRK
27 Mar 24
improved multiple secondary outcome measures, including reducing the risk of death from any cause or PAH clinical worsening events by 84% versus
6pm407bd0whbdit42p0jishgg2ii7132fh0nw85e
ATNM
AZN
BMY
25 Mar 24
-enlarging cysts that impair kidney function, potentially leading to kidney failure or premature death. Currently, an estimated 250,000 individuals
577psgf2a8y818j1v4zg0yvmq9qvq0e8vcu7iwm0
BMY
23 Mar 24
CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted
xwodhj
BMY
20 Mar 24
of disease progression or death and a well-established safety profile with mostly low-grade and transient occurrences of cytokine release syndrome
nrosy80xo3nfam7hjpe03rsd1nqyoelea4geqkz19cz4pe
BMY
20 Mar 24
demonstrated superiority over standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well
pdzvm9o8r870ftokk6ko9f4i6v5gqfaay58f8zvel3
BMY
19 Mar 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
pe63ij13ppaxzbz8vr12vd3pj0 4qed05v6ot7dfuecn
BMY
TSVT
15 Mar 24
) of patients receiving ABECMA, including Grade 3 in 4% (5/127) of patients. One patient had ongoing Grade 2 neurotoxicity at the time of death. Two
qive ep0h14nn2puaakgkohn3r4818
BMY
14 Mar 24
CRS in 4.1% of patients. One patient had fatal CRS and 2 had ongoing CRS at time of death. The median time to onset was 5 days (range: 1 to 15 days